Get the Stockscreener App
2.63
3.14%
0.08
After Hours:
2.63
Kiora Pharmaceuticals Inc stock is traded at $2.63, with a volume of 17,249.
It is up +3.14% in the last 24 hours and up +2.33% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$2.55
Open:
$2.54
24h Volume:
17,249
Relative Volume:
0.42
Market Cap:
$11.66M
Revenue:
$20,000
Net Income/Loss:
$-11.06M
P/E Ratio:
-0.9245
EPS:
-2.8449
Net Cash Flow:
$-10.53M
1W Performance:
+4.78%
1M Performance:
+2.33%
6M Performance:
+21.76%
1Y Performance:
-16.51%
1-Day Range:
$2.50
$2.63
1-Week Range:
$2.43
$2.63
52-Week Range:
$1.7645
$3.29
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
858-224-9600
Address
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.63 | 11.30M | 20,000 | -11.06M | -10.53M | -2.8449 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – FWB:7EY - TradingView
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – LS:A40EG5 - TradingView
Kiora Pharmaceuticals Inc. (KPRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – GETTEX:7EY - TradingView
Price to book forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
KPRXKiora Pharmaceuticals Inc Latest SEC Filings - Finviz
Form 4 Kiora Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com India
Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations - Stock Titan
[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector WatchesRelative Volume - dars.gov.et
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium - TMX Newsfile
Kiora Pharmaceuticals Inc Warrant 2022-27.09.27 on Kiora Pharma A Financial Disclosures & SEC Filings - TradingView
Kiora Pharmaceuticals (KPRX) Slides Marginally as Biotech Sector Remains CautiousStock Analysis - dars.gov.et
Kiora Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:KPRX) - TradingView
KPRX Forecast — Price Target — Prediction for 2027 - TradingView
7EY Forecast — Price Target — Prediction for 2027 - TradingView
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX) - The Globe and Mail
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Kiora Pharmaceuticals’ KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 – Minichart - Minichart
Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model - TMX Newsfile
Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kiora's KIO-300 cut epileptiform activity in epilepsy model - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares - Stock Titan
Kiora Pharmaceuticals (KPRX) director receives 25,000 stock options grant - Stock Titan
Director at Kiora (KPRX) receives 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director granted 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director awarded 25,000 stock options - Stock Titan
Kiora (KPRX) director Praveen Tyle receives stock options for 40,000 shares - Stock Titan
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan - TipRanks
Kiora Pharmaceuticals (NASDAQ: KPRX) OKs 1.5M-share equity plan boost and re-elects directors - Stock Titan
Kiora Pharmaceuticals (KPRX) Slips 4.9% as Stock Tests Key Support LevelsAD Line Divergence - newsline.com
Kiora Pharmaceuticals (KPRX) registers 11.8M shares including warrants - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector Faces HeadwindsTrading Ideas - The Legal Advocate
[EFFECT] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
Kiora Pharmaceuticals (KPRX) Rallies 5.5%: Key Levels to Watch After Recent UptickIV Spike - dars.gov.et
Kiora Pharmaceuticals (KPRX) Slips 4.5% as Stock Tests Key Support LevelDealer Gamma - The Legal Advocate
Kiora Pharmaceuticals Q1 2026 Earnings: EPS Beat Masks Continued Pre-Revenue Status as Stock SlipsAnalyst Drop Coverage - Newser
Kiora Pharmaceuticals (NASDAQ: KPRX) registers 11.8M resale shares - Stock Titan
Nantahala reports 9.99% stake in Kiora Pharmaceuticals (KPRX) - Stock Titan
Alyeska files 13G for Kiora (NASDAQ: KPRX) reporting 9.99% stake - Stock Titan
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):